oxazoles has been researched along with Apoplexy in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Fischer, N; Lebrun, F; Letourneur, A; Levilly, A; Muller, C; Orset, C; Sors, A; Violle, N; Vivien, D | 1 |
| Audoli, ML; Bassetti, CL; Chabriat, H; Gruget, C; Hermann, DM; Marx, U; Picarel-Blanchot, F; Saba, B; Sors, A; Wattez, M | 1 |
| Cramer, SC | 1 |
| Audoli-Inthavong, ML; Bassetti, CL; Chabriat, H; Hermann, DM; Lambert, E; Marx, U; Sors, A; Wattez, M | 1 |
| Buse, JB; Grobbee, DE; Henry, RR; Lincoff, AM; Malmberg, K; Mellbin, L; Neal, B; Nicholls, SJ; Nozza, A; Rydén, L; Schrieks, IC; Schwartz, GG; Stähli, BE; Svensson, A; Tardif, JC; Wedel, H; Weichert, A | 1 |
| Bassetti, CL; Doeppner, TR; Dzyubenko, E; Hermann, DM; Kaltwasser, B; Kleinschnitz, C; Machado, P; Sanchez-Mendoza, EH; Sardari, M; Silva de Carvalho, T; Wang, YC | 1 |
| Boujon, V; Endres, M; Gertz, K; Kronenberg, G; Laufs, U; Uhlemann, R; Wegner, S; Wright, MB | 1 |
| Buse, JB; Cannata, R; Grobbee, DE; Henry, RR; Lincoff, AM; Malmberg, K; Neal, B; Nicholls, SJ; Rydén, L; Schwartz, GG; Tardif, JC; Wedel, H; Weichert, A | 1 |
| Buse, JB; Cannata, R; Grobbee, DE; Henry, RR; Lincoff, AM; Malmberg, K; Neal, B; Nicholls, SJ; Rydén, L; Schwartz, GG; Svensson, A; Tardif, JC; Volz, D; Wedel, H; Weichert, A | 1 |
| Bengus, M; Califf, R; Ditmarsch, M; Erdmann, E; Gerstein, HC; Malmberg, K; Ruilope, L; Schwartz, GG; Svensson, A; Volz, D; Wedel, H | 1 |
| Grover, GJ; Rosenfeld, L; Stier, CT | 1 |
1 review(s) available for oxazoles and Apoplexy
| Article | Year |
|---|---|
Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist.
Topics: Animals; Bridged Bicyclo Compounds, Heterocyclic; Humans; Hypertension; Muscle Contraction; Muscle, Smooth, Vascular; Myocardial Ischemia; Oxazoles; Platelet Aggregation Inhibitors; Prostaglandin H2; Prostaglandins H; Randomized Controlled Trials as Topic; Receptors, Prostaglandin; Receptors, Thromboxane; Stroke; Thrombosis; Thromboxane A2 | 2001 |
6 trial(s) available for oxazoles and Apoplexy
| Article | Year |
|---|---|
Randomized Efficacy and Safety Trial with Oral S 44819 after Recent ischemic cerebral Event (RESTORE BRAIN study): a placebo controlled phase II study.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Benzodiazepines; Brain Ischemia; Double-Blind Method; Female; GABA-A Receptor Antagonists; Humans; Intracranial Hemorrhages; Male; Mental Status and Dementia Tests; Middle Aged; Oxazoles; Recovery of Function; Stroke; Treatment Outcome; Young Adult | 2020 |
Safety and efficacy of GABA
Topics: Adult; Aged; Aged, 80 and over; Benzodiazepines; Brain; Brain Ischemia; Double-Blind Method; Female; GABA Antagonists; GABA-A Receptor Antagonists; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Oxazoles; Stroke; Treatment Outcome | 2020 |
Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adiponectin; Aged; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Nonesterified; Female; Humans; Male; Middle Aged; Myocardial Infarction; Oxazoles; Retrospective Studies; Stroke; Thiophenes; Treatment Outcome | 2018 |
Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hospitalization; Humans; Male; Middle Aged; Morbidity; Myocardial Infarction; Oxazoles; Peroxisome Proliferator-Activated Receptors; Risk Factors; Stroke; Thiophenes; Treatment Outcome | 2013 |
Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Myocardial Infarction; Oxazoles; Peroxisome Proliferator-Activated Receptors; Risk; Stroke; Survival Analysis; Thiophenes; Treatment Outcome | 2014 |
Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.
Topics: Aged; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Early Termination of Clinical Trials; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Myalgia; Myocardial Infarction; Myositis; Oxazoles; Peripheral Arterial Disease; PPAR alpha; PPAR gamma; Prediabetic State; Stroke; Thiophenes; Treatment Outcome | 2015 |
5 other study(ies) available for oxazoles and Apoplexy
| Article | Year |
|---|---|
Post-acute delivery of α5-GABAA antagonist, S 44819, improves functional recovery in juvenile rats following stroke.
Topics: Animals; Benzodiazepines; GABA-A Receptor Antagonists; Male; Oxazoles; Rats; Rats, Sprague-Dawley; Recovery of Function; Stroke | 2022 |
Issues important to the design of stroke recovery trials.
Topics: Benzodiazepines; Brain Ischemia; Double-Blind Method; Humans; Oxazoles; Stroke; Stroke Rehabilitation | 2020 |
Postacute Delivery of GABA
Topics: Animals; Benzodiazepines; Brain; GABA Antagonists; Infarction, Middle Cerebral Artery; Male; Mice, Inbred C57BL; Neuronal Plasticity; Neurons; Neuroprotection; Oxazoles; Receptors, GABA-A; Recovery of Function; Stroke | 2018 |
Dual PPARα/γ agonist aleglitazar confers stroke protection in a model of mild focal brain ischemia in mice.
Topics: Animals; Brain Ischemia; Disease Models, Animal; Mice; Oxazoles; PPAR alpha; PPAR gamma; Stroke; Thiophenes | 2019 |
A bumpy road to breakthroughs. The news: it's hard to beat today's cardiac treatments.
Topics: Animals; Atherosclerosis; Coronary Thrombosis; Diabetes Mellitus, Type 2; Ethics, Clinical; Glycine; Heart Failure; Humans; Indoleacetic Acids; Myocardial Infarction; Oxazoles; Prostheses and Implants; Stroke; Treatment Failure; Ultrasonography | 2006 |